TIDMHIK
RNS Number : 4938W
Hikma Pharmaceuticals Plc
23 April 2021
Hikma Pharmaceuticals PLC
Voting Results of 2021 Annual General Meeting
LONDON, 23 April 2021 Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75)
announces its Annual General Meeting ("AGM"), held at 1 New
Burlington Place, W1S 2HR, London on 23 April 2021 commenced at
1:00 pm. All resolutions were duly passed by shareholders by way of
a poll. Resolutions 1 to 15 and 17 were passed as ordinary
resolutions and Resolutions 16 and 18 to 22 were passed as special
resolutions.
Copies of the resolutions dealing with special business passed
at the AGM have been submitted to the to the FCA's Electronic
Submission System and will be available from the National Storage
Mechanism.
The total number of votes cast on the poll for each resolution
(the full text of the resolutions is detailed in the notice of the
AGM dated 24 February 2021) is set out below. The number of
Ordinary Shares in issue on 23 April 2021 was 243,604,637. There
were 12,833,233 Ordinary Shares held in treasury, which are not
counted in the voting capital of the Company which, therefore, was
230,771,404.
Resolution Votes For % Votes Against % Total Cast Withheld
1. To receive the
2020 report and
accounts 176,723,133 100.0 16,692 0 176,739,825 1,537,096
------------ ------ -------------- ----- ------------ ----------
2. To approve a
final dividend of
34 cents per share 178,275,824 100.0 152 0 178,275,976 945
------------ ------ -------------- ----- ------------ ----------
3. To re-appoint
PricewaterhouseCoopers
LLP as auditors 177,053,202 99.3 1,222,474 0.7 178,275,676 1,245
------------ ------ -------------- ----- ------------ ----------
4. To authorise
the Audit Committee
to determine the
auditors' remuneration 178,174,755 99.9 100,365 0.1 178,275,120 1,801
------------ ------ -------------- ----- ------------ ----------
5. To elect Douglas
Hurt as a director 174,859,594 98.1 3,414,131 1.9 178,273,725 3,196
------------ ------ -------------- ----- ------------ ----------
6. To re-elect
Said Darwazah as
a director 171,553,543 97.2 4,923,908 2.8 176,477,451 1,799,470
------------ ------ -------------- ----- ------------ ----------
7. To re-elect
Siggi Olafsson as
a director 176,112,071 98.8 2,163,336 1.2 178,275,407 1,514
------------ ------ -------------- ----- ------------ ----------
8. To re-elect
Mazen Darwazah as
a director 171,246,066 96.1 6,949,669 3.9 178,195,735 81,186
------------ ------ -------------- ----- ------------ ----------
9. To re-elect
Patrick Butler as
a director 172,831,258 97.0 5,434,621 3.1 178,265,879 11,041
------------ ------ -------------- ----- ------------ ----------
10. To re-elect
Ali Al-Husry as
a director 175,142,703 98.3 3,053,032 1.7 178,195,735 81,186
------------ ------ -------------- ----- ------------ ----------
11. To re-elect
Dr. Pamela Kirby
as a director 167,790,753 95.1 8,655,778 4.9 176,446,531 1,830,390
------------ ------ -------------- ----- ------------ ----------
12. To re-elect
John Castellani
as a director 175,101,327 98.9 1,975,760 1.1 177,077,087 1,199,834
------------ ------ -------------- ----- ------------ ----------
13 . To re-elect
Nina Henderson as
a director 175,403,863 98.4 2,871,070 1.6 178,274,933 1,988
------------ ------ -------------- ----- ------------ ----------
14 . To re-elect
Cynthia Schwalm
as a director 154,099,252 86.5 24,120,681 13.5 178,219,933 56,988
------------ ------ -------------- ----- ------------ ----------
15. To approve
the remuneration
report for the year
ended 31 December
2020 160,014,990 90.4 17,063,364 9.6 177,078,354 1,198,566
------------ ------ -------------- ----- ------------ ----------
16. To approve
the adoption of
the new articles
of association for
the Company 177,680,870 99.7 593,294 0.3 178,274,164 2,757
------------ ------ -------------- ----- ------------ ----------
17. Authority to
allot shares 154,848,864 86.9 23,426,822 13.1 178,275,686 1,235
------------ ------ -------------- ----- ------------ ----------
18 . To dis-apply
pre-emption rights
for general purposes 177,563,944 99.6 711,824 0.4 178,275,768 1,153
------------ ------ -------------- ----- ------------ ----------
19. To dis-apply
pre-emption rights
for an acquisition
or other capital
investment 174,606,709 97.9 3,668,585 2.1 178,275,294 1,627
------------ ------ -------------- ----- ------------ ----------
20. To authorise
the Company to purchase
its own shares 176,712,127 99.2 1,480,842 0.8 178,192,969 83,952
------------ ------ -------------- ----- ------------ ----------
21. To authorise
the Company to hold
general meetings
on no less than
14 clear days' notice 169,544,820 95.1 8,731,027 4.9 178,275,847 1,074
------------ ------ -------------- ----- ------------ ----------
Declaration of final dividend
The dividend of 34 cents per share will be paid on 26 April 2021
to shareholders on the register on 19 March 2021. Shareholders who
are not resident in Jordan have been given the option of receiving
their dividend in Pounds Sterling. The exchange rate in respect of
this dividend will be $1.3762998 to GBP1. The exchange rate for
Jordanian Dinar is fixed to the US Dollar at circa $1 to
0.709JD.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
Susan Ringdal
EVP, Strategic Planning and Global Affairs +44 20 7399 2670
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSEUFLDEFSEDL
(END) Dow Jones Newswires
April 23, 2021 10:51 ET (14:51 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024
